Company news
Hoth Therapeutics, Inc. news in 2026
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Hoth Therapeutics: Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
June 15, 2026
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
May 26, 2026
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nan...
May 18, 2026
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 5, 2026
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
April 14, 2026
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
April 1, 2026
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
March 31, 2026
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
March 30, 2026
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
March 25, 2026
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
March 23, 2026
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
March 9, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
March 4, 2026
HOTH Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases
February 24, 2026
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
February 12, 2026
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
February 10, 2026
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
February 5, 2026
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
January 22, 2026
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
January 21, 2026
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
January 15, 2026
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
January 2, 2026